

# Borderline Left Ventricle: Does the Size Matter?



*Jan Marek*

Great Ormond Street Hospital  
&  
Institute of Cardiovascular Sciences,  
University College London

*No disclosures*

**Aim of treatment:**

**best possible quality  
of life  
at longest lifetime**

# Critical AS: main considerations:

- **Biventricular circulation:**

- Balloon valvuloplasty, Ross(Konno)

- Mitral valve repair/ replacement (Melody/Prosthetic)

- AO valve repair/replacement

- Homograft replacements <sup>(n-1)</sup>

- EFE resection/LV rehabilitation

- Postcapillary hypertension (LVAD/HTx / H+LTx)

- **Uni-ventricular circulation (Fontan):**

- Norwood I, BCPA, TCPC

- **Heart transplant:**

- Later HTx (10y-survival 85% at GOSH), re-HTx?

- Availability (no neonatal donors in Europe)

# Critical AS: main considerations:

- **Biventricular circulation:**

  - Balloon valvuloplasty, Ross(Konno)

  - Mitral valve repair/ replacement (Melody/Prosthetic)

  - AO valve repair/replacement

  - Homograft replacements <sup>(n-1)</sup>

  - EFE resection/LV rehabilitation

  - Postcapillary hypertension (LVAD/HTx / H+LTx)

- **Uni-ventricular circulation (Fontan):**

  - Norwood I, BCPA, TCPC

- **Heart transplant:**

  - Later HTx (10y-survival 85% at GOSH), re-HTx?


  - Availability (no neonatal donors in Europe)

# 40-Year Follow-Up After the Fontan Operation

Long-Term Outcomes of 1,052 Patients (Mayo experience)


**TABLE 1** Patient Demographics (N = 1,052)

Male	637 (61)
Type of Fontan operation	
Atriopulmonary connection	616 (59)
Lateral tunnel	262 (25)
<b>Extracardiac conduit</b>	<b>120 (11)</b>
Other	54 (5)




# 40-Year Follow-Up After the Fontan Operation



Long-Term Outcomes of 1,052 Patients (Mayo experience)



**TCPC**  
**Extracardiac**  
**Conduit**



# Critical Aortic Stenosis: 40y follow up (GOSH, N=96, 1970-2010)



# Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome: Postnatal Outcomes of the First 100 Patients

Lindsay R. Freud, MD<sup>1</sup>, Doff B. McElhinney, MD<sup>1</sup>, Audrey C. Marshall, MD<sup>1</sup>, Gerald R. Marx, MD<sup>1</sup>, Kevin G. Friedman, MD<sup>1</sup>, Pedro J. del Nido, MD<sup>2</sup>, Sitaram M. Emani, MD<sup>2</sup>, Terra Lafranchi, NP-C<sup>1</sup>, Virginia Silva, RN<sup>3</sup>, Louise E. Wilkins-Haug, MD, PhD<sup>3</sup>, Carol B. Benson, MD<sup>4</sup>, James E. Lock, MD<sup>1</sup>, and Wayne Tworetzky, MD<sup>1</sup>








Figure 2. Flow diagram summarizing postnatal management and outcomes for the entire 100 patient cohort. (HLHS=hypoplastic left heart syndrome)



# Fetal intrauterine balloon aortic valvuloplasty: Postnatal neonatal outcome



- Postnatal cardiogenic shock
- Unable to stabilise circulation
- Not for Ross / Konno

# Cardiogenic shock in infancy

## Cardiac aetiology

- Reduced diastolic filling:

**PFC / PPH, TAPVC**

- Reduced ejection fraction:

**AS, COA**

- Combination of both:

**HLHS, AS, HLV, COA, EFE**




# SMALL LEFT VENTRICLE

## Primarily or secondarily small?

Small left ventricle in overloaded (pressure, volume) right ventricle is primarily not only due to compression; rather is due to underfilling

- TAPVC
- Isolated COA
- PPH/PFC



LV can stretch more than anticipated (elastic stocking vs. plastic bag)

**Even “hypoplastic” LV cavity < 15-20 ml/m<sup>2</sup> can expand to adequate volume**

**CRITICAL AORTIC STENOSIS IN THE NEONATE: A MULTI-INSTITUTIONAL STUDY OF MANAGEMENT, OUTCOMES, AND RISK FACTORS**

Initially intended BIV (116)

- 5yr survival rate 70%

Initially UNIV (179)

- 5yr survival rate 60%

Independent risk factors associated with greater survival benefit for BIV versus UNIV:

- Age
- Aortic valve Z-score
- LV length
- Endocardial fibroelastosis
- Tricuspid regurgitation
- Ascendent aorta

Multivariable hazard model

*Lofland GK, JTCVS 2001, Hickey EJ, JTCVS 2007*

[http://www.ctsnet.org/aortic\\_stenosis\\_calc/](http://www.ctsnet.org/aortic_stenosis_calc/)

**Calculator**

# Critical AS: Late outcome

**TT, 15 yrs**

**Critical AS**

**S/P valvotomy (2d)+ECMO**

**S/P Balloon VPL (6yrs)**

**Ross-Konno (at 9yrs)**

**PPVI (15yrs) – post: PA wedge 23 mmHg**

**YM, 15 yrs**

**Critical AS**

**S/P valvotomy (3d)**

**S/P Ross (at 3yrs)**


**Progressive PH, Stroke (12yrs)**

**PPVI (13yrs) – post:**



**MPA 75/34/36 Ao 80/42/56**

**Waiting list H+LTx**

**Died (15yrs)**



# Endocardial fibroelastosis: ECHO



---

**Neither endocardial echo-brightness nor geometric variables of the left ventricle allow for accurate prediction of the presence of endocardial fibroelastosis.**


*Tworetzky W, Am J Cardiol 2005*

*Mahle WT, Am J Cardiol 1998*

*Colan SD, JACC 2006*

*McElhinney DB, Circulation 2009*

# Endocardial fibroelastosis: MRI





## Late gadolinium enhancement:

- Inversely related to HR
- Contraindicated in LCO (nephrotoxicity)

# Obstructive Left Heart Disease in Neonates With a “Borderline” Left Ventricle: Diagnostic Challenges to Choosing the Best Outcome

Giulia Tuo · Sachin Khambadkone ·  
 Oliver Tann · Martin Kostolny · Graham Derrick ·  
 Victor Tsang · Ian Sullivan · Jan Marek








# Endocardial fibroelastosis resection

- No operative mortality, median follow-up 25 months (6m - 10y)
- 1 death from noncardiac causes, 2 reoperations (1 x MVR, 1 x AO + MV repair)
- 3 pts. recurrent EFE

	Preop	Recent	p
LVEDV Z-score	-0.2±1.7	2.7 ±1.8	<0.01
RV:LV SP ratio	0.78 ±0.36	0.32 ±0.11	<0.05
LAp (mmHg)	28 ±6.3	11 ±2.4	<0.01
EF (%)	36 ±12	58 ±10	<0.01
AO grad (mmHg)	39 ±22	28 ±19	NS

# LV Mechanical assist device as Bridge - to - HTx

## Heart Transplantation in a 14-Year-Old Boy in the Presence of Severe Out-of-Proportion Pulmonary Hypertension due to Restrictive Left Heart Disease: A Case Report



# Critical AS: Late outcome

## LV Mechanical assist device as **Bridge - to - HTx**

- **O<sub>2</sub>**
- **Epoprostenol (22 ng/kg/min)**
- **Sildenafil (0.5-2.0 mg/kg/4h)**
- **Bosentan (2-4 mg/kg)**
- **Diuretics and anticoagulants**

- Unloading the LV + LA hypertension
- Decreases postcapillary wedge pressure
- Induces a decline in the PAP
- Less hypoxia at the tissue level
  - reduces an important stimulant of pulmonary vasoconstriction

# Role of paediatric assist device in bridge to transplant

## Berlin, N=78

### Diagnosis

DCMP

56

Myocarditis

14

End-stage CHD

5

Ischemic heart failure

2

Tumour

1

Cardiopulmonary resuscitation



15

ECMO prior to VAD

7

# Role of paediatric assist device in bridge to transplant

## Berlin, N=78



- VAD implantation in “small” LV?
- Donor availability

# Critical Aortic Stenosis

- **Myocardial function rather than the size!?**
- **Role of endocardial fibroelastosis (EFE) and myocardial fibrosis**

# **Critical Aortic Stenosis**

**Fetal atrial stenting  
rather than  
fetal balloon valvuloplasty  
to offer better Fontan  
outcome ?**

# Echocardiography & Prenatal Cardiology

Director Jan Marek

## ***Clinical ECHO Consultants***

Michelle Carr  
Ram Awat  
Georgi Christov  
Beatrice Bonello

## ***Prenatal Cardiol. Consultants***

Ian Sullivan  
Robert Yates  
Shankar Sridharan  
Rachel Andrews  
Niki Manning

## ***Fetal Sonographers***

Jo Wolfenden  
Nicola Callaghan

## ***Cardiac Sonographers***

Gill Riley  
Ian McLeod  
Rebecca Banks  
Sarla Kataria  
Kalaiiarasi Janagarajan  
Jabeen Bibi  
Sally Punzal  
Sharmila Govinde  
Emma Chokdar  
Victoria Cable  
Rachel Woods

## ***ECHO Research Fellows***

Elodie Perdreau  
Ilaria Bo  
Anna Argiolas  
Ioanna Giannakopoulou

## ***Specialists Registrars***


William Regan  
Filip Kucera  
Sadia Qyam  
Salim Jivanji  
Corina Pauls  
William Regan  
Gabrielle Norish






# 40-Year Follow-Up After the Fontan Operation

Long-Term Outcomes of 1,052 Patients (Mayo experience)



# Fetal hemodynamic response to aortic valvuloplasty and postnatal outcome: a European multicenter study



**FVP short outcome: 19/67 (28%) BiV**